目的 研究乳腺癌患者雌激素受體（ER）、孕激素受體（PR）、人表皮生長因子受體2（HER-2）表達情況及免疫組織化學分子亞型分布。 方法 對2003年1月－2008年9月四川大學華西醫院病理科3 365例乳腺癌病理報告存檔資料進行激素受體（ER/PR）、HER-2表達情況及免疫組織化學分子亞型分布進行分析。 結果 3 365例確診的乳腺癌患者中，ER陽性1 824例（54.2%），PR陽性1 841例（54.7%），HER-2過表達284例（8.4%）。相關分析顯示ER與PR表達呈正相關（P＜0.001），HER-2與ER、PR表達均呈負相關（P＜0.001）。免疫組織化學分子亞型結果顯示luminal A型最常見，為1 993例（59.2%）；basal-like型為623例（18.5%）；HER-2過表達型為169例（5.0%）；luminal B型最少，為115例（3.4%）；未分類的為465例（13.8%）。 結論 乳腺癌患者激素受體及HER-2表達有特殊性，激素受體陽性率＞50%，HER-2陽性率在不同研究中顯示出不同的結果，尚需進一步研究；ER、PR與HER-2具有良好的相關性；免疫組織化學分子亞型中luminal A型最常見。
ObjectiveTo formulate the Chinese version of Fear of Progression Questionnaire-Short Form/Caregiver Version (FoP-Q-SF/C) and examine the reliability and validity of the scale.MethodsA questionnaire survey of FoP-Q-SF/C was conducted among the caregivers of melanoma out-patients in West China Hospital of Sichuan University from June 2019 to March 2020. Convenient sampling method was adopted. The validity and reliability of the scale were analyzed.ResultsA total of 247 caregivers of melanoma out-patients were investigated by the FoP-Q-SF/C, and 101 valid questionnaires were finally collected. The Cronbach’s α of the FoP-Q-SF/C scale was 0.919, and the Guttman Split-Half coefficient was 0.906. Using exploratory factor analysis to extract 3 common factors, the cumulative explainable total variation was 73.964%. The model fit was as follows: chi-square/degree of freedom was 1.950, standardized root mean square residual was 0.067, goodness of fit index was 0.859, incremental fit index was 0.939, comparative fit index was 0.938, Tucker-Lewis index or non-normed fit index was 0.918, and the root-mean-square error of approximation was 0.097.ConclusionsThe FoP-Q-SF/C scale formulated in this study is divided into three dimensions, which has good reliability and validity, meanwhile, it is relatively simple and can be used to clinically screen melanoma caregivers’ FoP-Q-SF/C levels. However, the application of this scale in other diseases still needs further testing.